Copyright Reports & Markets. All rights reserved.

Global Herpes Zoster Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Herpes Zoster Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Oral
      • 1.4.3 Topical
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Herpes Zoster Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Home Care Settings
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Herpes Zoster Treatment Market Size
    • 2.2 Herpes Zoster Treatment Growth Trends by Regions
      • 2.2.1 Herpes Zoster Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Herpes Zoster Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Herpes Zoster Treatment Market Size by Manufacturers
      • 3.1.1 Global Herpes Zoster Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Herpes Zoster Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Herpes Zoster Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Herpes Zoster Treatment Key Players Head office and Area Served
    • 3.3 Key Players Herpes Zoster Treatment Product/Solution/Service
    • 3.4 Date of Enter into Herpes Zoster Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Herpes Zoster Treatment Market Size by Type (2014-2019)
    • 4.2 Global Herpes Zoster Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Herpes Zoster Treatment Market Size (2014-2019)
    • 5.2 Herpes Zoster Treatment Key Players in United States
    • 5.3 United States Herpes Zoster Treatment Market Size by Type
    • 5.4 United States Herpes Zoster Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Herpes Zoster Treatment Market Size (2014-2019)
    • 6.2 Herpes Zoster Treatment Key Players in Europe
    • 6.3 Europe Herpes Zoster Treatment Market Size by Type
    • 6.4 Europe Herpes Zoster Treatment Market Size by Application

    7 China

    • 7.1 China Herpes Zoster Treatment Market Size (2014-2019)
    • 7.2 Herpes Zoster Treatment Key Players in China
    • 7.3 China Herpes Zoster Treatment Market Size by Type
    • 7.4 China Herpes Zoster Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Herpes Zoster Treatment Market Size (2014-2019)
    • 8.2 Herpes Zoster Treatment Key Players in Japan
    • 8.3 Japan Herpes Zoster Treatment Market Size by Type
    • 8.4 Japan Herpes Zoster Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Herpes Zoster Treatment Market Size (2014-2019)
    • 9.2 Herpes Zoster Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Herpes Zoster Treatment Market Size by Type
    • 9.4 Southeast Asia Herpes Zoster Treatment Market Size by Application

    10 India

    • 10.1 India Herpes Zoster Treatment Market Size (2014-2019)
    • 10.2 Herpes Zoster Treatment Key Players in India
    • 10.3 India Herpes Zoster Treatment Market Size by Type
    • 10.4 India Herpes Zoster Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Herpes Zoster Treatment Market Size (2014-2019)
    • 11.2 Herpes Zoster Treatment Key Players in Central & South America
    • 11.3 Central & South America Herpes Zoster Treatment Market Size by Type
    • 11.4 Central & South America Herpes Zoster Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Herpes Zoster Treatment Introduction
      • 12.1.4 Roche Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Herpes Zoster Treatment Introduction
      • 12.2.4 Novartis Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Merck
      • 12.3.1 Merck Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Herpes Zoster Treatment Introduction
      • 12.3.4 Merck Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.3.5 Merck Recent Development
    • 12.4 GlaxoSmithKline
      • 12.4.1 GlaxoSmithKline Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Herpes Zoster Treatment Introduction
      • 12.4.4 GlaxoSmithKline Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.4.5 GlaxoSmithKline Recent Development
    • 12.5 Abbott Laboratories
      • 12.5.1 Abbott Laboratories Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Herpes Zoster Treatment Introduction
      • 12.5.4 Abbott Laboratories Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.5.5 Abbott Laboratories Recent Development
    • 12.6 Astellas Pharma
      • 12.6.1 Astellas Pharma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Herpes Zoster Treatment Introduction
      • 12.6.4 Astellas Pharma Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.6.5 Astellas Pharma Recent Development
    • 12.7 Bausch Health Companies
      • 12.7.1 Bausch Health Companies Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Herpes Zoster Treatment Introduction
      • 12.7.4 Bausch Health Companies Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.7.5 Bausch Health Companies Recent Development
    • 12.8 Teva Pharmaceutical
      • 12.8.1 Teva Pharmaceutical Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Herpes Zoster Treatment Introduction
      • 12.8.4 Teva Pharmaceutical Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.8.5 Teva Pharmaceutical Recent Development
    • 12.9 Foamix Pharmaceuticals
      • 12.9.1 Foamix Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Herpes Zoster Treatment Introduction
      • 12.9.4 Foamix Pharmaceuticals Revenue in Herpes Zoster Treatment Business (2014-2019)
      • 12.9.5 Foamix Pharmaceuticals Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Herpes Zoster, also known as zoster or shingles, is a viral disease characterized by a painful skin rash with blisters in a localized area. Typically the rash occurs in a single, wide stripe either on the left or right side of the body or face. Two to four days before the rash occurs there may be tingling or local pain in the area. Otherwise there are typically few symptoms though some may have fever, headache, or feel tired. The rash usually heals within two to four weeks; however, some people develop ongoing nerve pain which can last for months or years, a condition called postherpetic neuralgia (PHN). In those with poor immune function the rash may occur widely. If the rash involves the eye, vision loss may occur.
      In 2018, the global Herpes Zoster Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Herpes Zoster Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Herpes Zoster Treatment development in United States, Europe and China.

      The key players covered in this study
      Roche
      Novartis
      Merck
      GlaxoSmithKline
      Abbott Laboratories
      Astellas Pharma
      Bausch Health Companies
      Teva Pharmaceutical
      Foamix Pharmaceuticals

      Market segment by Type, the product can be split into
      Oral
      Topical
      Others

      Market segment by Application, split into
      Hospitals
      Clinics
      Home Care Settings

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Herpes Zoster Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Herpes Zoster Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Herpes Zoster Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now